Hemosol Inc., Fresenius AG deal

HML received a C$2.1 million (US$1.4 million) milestone from partner Fresenius for starting a Phase III trial in the U.S. and the U.K. with its Hemolink crosslinked hemoglobin 10 percent solution to r...